These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38991462)

  • 21. Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.
    Bennett LD; Yang Q; Berquist BR; Giddens JP; Ren Z; Kommineni V; Murray RP; White EL; Holtz BR; Wang LX; Marcel S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385073
    [No Abstract]   [Full Text] [Related]  

  • 22. Production of secretory and extracellular N-linked glycoproteins in Escherichia coli.
    Fisher AC; Haitjema CH; Guarino C; Çelik E; Endicott CE; Reading CA; Merritt JH; Ptak AC; Zhang S; DeLisa MP
    Appl Environ Microbiol; 2011 Feb; 77(3):871-81. PubMed ID: 21131519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of host cell line choice on glycan profile.
    Goh JB; Ng SK
    Crit Rev Biotechnol; 2018 Sep; 38(6):851-867. PubMed ID: 29262720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycoengineering of CHO Cells to Improve Product Quality.
    Wang Q; Yin B; Chung CY; Betenbaugh MJ
    Methods Mol Biol; 2017; 1603():25-44. PubMed ID: 28493121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoenzymatic Methods for the Synthesis of Glycoproteins.
    Li C; Wang LX
    Chem Rev; 2018 Sep; 118(17):8359-8413. PubMed ID: 30141327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycan-Based Cell Targeting To Modulate Immune Responses.
    Johannssen T; Lepenies B
    Trends Biotechnol; 2017 Apr; 35(4):334-346. PubMed ID: 28277249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging facets of prokaryotic glycosylation.
    Schäffer C; Messner P
    FEMS Microbiol Rev; 2017 Jan; 41(1):49-91. PubMed ID: 27566466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.
    Sha S; Agarabi C; Brorson K; Lee DY; Yoon S
    Trends Biotechnol; 2016 Oct; 34(10):835-846. PubMed ID: 27016033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homogeneously N-glycosylated proteins derived from the GlycoDelete HEK293 cell line enable diffraction-quality crystallogenesis.
    Kozak S; Bloch Y; De Munck S; Mikula A; Bento I; Savvides SN; Meijers R
    Acta Crystallogr D Struct Biol; 2020 Dec; 76(Pt 12):1244-1255. PubMed ID: 33263330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-based glycoengineering of extracellular vesicles through precise genome editing.
    Tian W; Zagami C; Chen J; Blomberg AL; Guiu LS; Skovbakke SL; Goletz S
    N Biotechnol; 2024 Nov; 83():101-109. PubMed ID: 39079597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins.
    Meuris L; Santens F; Elson G; Festjens N; Boone M; Dos Santos A; Devos S; Rousseau F; Plets E; Houthuys E; Malinge P; Magistrelli G; Cons L; Chatel L; Devreese B; Callewaert N
    Nat Biotechnol; 2014 May; 32(5):485-9. PubMed ID: 24752077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycosylation control technologies for recombinant therapeutic proteins.
    Gupta SK; Shukla P
    Appl Microbiol Biotechnol; 2018 Dec; 102(24):10457-10468. PubMed ID: 30334089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin.
    Zemella A; Thoring L; Hoffmeister C; Šamalíková M; Ehren P; Wüstenhagen DA; Kubick S
    Sci Rep; 2018 Jun; 8(1):8514. PubMed ID: 29867209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
    Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Bacterial Oligosaccharyltransferase Structure Elucidation and Potential Application to Glycoconjugate Vaccine Design.
    Lu R; Li P; Zhu L; Chang MX; Ouyang S
    Front Biosci (Landmark Ed); 2023 Nov; 28(11):305. PubMed ID: 38062836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding protein glycosylation pathways in bacteria.
    Li H; Debowski AW; Liao T; Tang H; Nilsson HO; Marshall BJ; Stubbs KA; Benghezal M
    Future Microbiol; 2017 Jan; 12():59-72. PubMed ID: 27689684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering.
    Liang C; Chiang AWT; Hansen AH; Arnsdorf J; Schoffelen S; Sorrentino JT; Kellman BP; Bao B; Voldborg BG; Lewis NE
    Curr Res Biotechnol; 2020 Nov; 2():22-36. PubMed ID: 32285041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.
    Pan C; Sun P; Liu B; Liang H; Peng Z; Dong Y; Wang D; Liu X; Wang B; Zeng M; Wu J; Zhu L; Wang H
    mBio; 2016 Apr; 7(2):e00443-16. PubMed ID: 27118590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
    Saunders MJ; Woods RJ; Yang L
    Sci Rep; 2023 Jan; 13(1):567. PubMed ID: 36631484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding.
    Margolin E; Crispin M; Meyers A; Chapman R; Rybicki EP
    Front Plant Sci; 2020; 11():609207. PubMed ID: 33343609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.